Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Starpharma Holdings Limited (SPL.AX)
AUD0.73
-0.03 (-3.31%)
AU ASX Healthcare Biotechnology
Address
4-6 Southampton Crescent 3067
Abbotsford, VIC, AU
Abbotsford, VIC, AU
CEO
Cheryl Maley
Website
starpharma.com
IPO
2000-09-27
ISIN AU000000SPL0
Also trades on
Australian Securities Exchange · SPL.AX (AUD)
Other OTC · SPHRF (USD)
Other OTC · SPHRY (USD)
Description
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.73
-0.03 (-3.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.77
Float Shares
319.74M
Free Float %
76.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.70% | +14.75% | -4.11% | +52.17% | +72.84% | +94.44% | +660.87% | +77.22% | -60.67% | -2.10% | -17.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.73
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
23.30
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-40.7% Q4'25: +50.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-20.7% Q4'25: +232.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-27.6% Q4'25: +33.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-244.3% Q4'25: -36.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-200.2% Q4'25: -233.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.4% ★ Q4'25: +2.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.22× Q4'25: -0.06× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2001 actual |
Jun 2002 actual |
Jun 2003 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.52M (-100.0%)
|
384.7K
est: 1.52M (-74.7%)
|
1.48M
est: 1.52M (-2.5%)
|
1.14M
est: 6.37M (-82.0%)
|
925.0K
est: 2.96M (-68.7%)
|
20.0K
est: 3.76M (-99.5%)
|
1.25M
est: 3.89M (-67.8%)
|
1.70M
est: 4.55M (-62.7%)
|
4.57M
est: 6.10M (-25.0%)
|
3.65M
est: 21.23M (-82.8%)
|
4.96M
est: 12.30M (-59.7%)
|
2.72M
est: 5.69M (-52.2%)
|
6.03M
est: 12.40M (-51.3%)
|
1.80M
est: 5.61M (-67.9%)
|
4.68M
est: 5.20M (-10.0%)
|
2.94M
est: 15.60M (-81.2%)
|
8.29M
est: 2.80M (+196.0%)
|
4.91M
est: 4.70M (+4.5%)
|
15.80M
15.80M – 15.80M
+236.2% YoY
|
24.00M
24.00M – 24.00M
+51.9% YoY
|
37.50M
37.50M – 37.50M
+56.3% YoY
|
55.00M
55.00M – 55.00M
+46.7% YoY
|
| EBITDA |
-5.52M
est: -1.52M (-262.7%)
|
-8.69M
est: -1.49M (-482.6%)
|
-6.92M
est: -1.49M (-364.0%)
|
-7.38M
est: -33.11M (+77.7%)
|
-12.51M
est: -4.16M (-200.9%)
|
-4.17M
est: -17.37M (+76.0%)
|
-13.53M
est: -4.72M (-186.9%)
|
-17.72M
est: -17.79M (+0.4%)
|
-21.74M
est: -30.66M (+29.1%)
|
-14.90M
est: -93.11M (+84.0%)
|
-11.43M
est: 3.25M (-451.3%)
|
-13.96M
est: -4.74M (-194.3%)
|
-19.44M
est: -27.37M (+29.0%)
|
-26.05M
est: -19.97M (-30.4%)
|
-22.34M
est: -43.78M (+49.0%)
|
-22.08M
est: -60.56M (+63.5%)
|
-9.63M
est: -98.98M (+90.3%)
|
-10.93M
est: -4.70M (-132.5%)
|
-15.80M
-15.80M – -15.80M
-236.2% YoY
|
-24.00M
-24.00M – -24.00M
-51.9% YoY
|
-37.50M
-37.50M – -37.50M
-56.3% YoY
|
-55.00M
-55.00M – -55.00M
-46.7% YoY
|
| EBIT |
-5.58M
est: -1.52M (-266.8%)
|
-8.87M
est: -1.49M (-494.2%)
|
-7.53M
est: -1.49M (-404.5%)
|
-8.91M
est: -33.32M (+73.2%)
|
-13.65M
est: -4.14M (-229.9%)
|
-5.22M
est: -17.35M (+69.9%)
|
-14.63M
est: -4.70M (-211.4%)
|
-18.95M
est: -17.77M (-6.6%)
|
-22.67M
est: -30.65M (+26.0%)
|
-15.22M
est: -87.42M (+82.6%)
|
-11.74M
est: -6.04M (-94.4%)
|
-15.62M
est: -4.74M (-229.4%)
|
-20.35M
est: -27.37M (+25.7%)
|
-26.98M
est: -19.97M (-35.1%)
|
-23.42M
est: -43.78M (+46.5%)
|
-23.27M
est: -60.56M (+61.6%)
|
-10.75M
est: -98.98M (+89.1%)
|
-12.00M
est: -4.70M (-155.3%)
|
-15.80M
-15.80M – -15.80M
-236.2% YoY
|
-24.00M
-24.00M – -24.00M
-51.9% YoY
|
-37.50M
-37.50M – -37.50M
-56.3% YoY
|
-55.00M
-55.00M – -55.00M
-46.7% YoY
|
| Net Income |
-3.91M
est: -21.91M (+82.2%)
|
53.2K
est: -29.54M (+100.2%)
|
-175.1K
est: -34.47M (+99.5%)
|
-8.93M
est: -33.11M (+73.0%)
|
-13.66M
est: -4.15M (-229.3%)
|
-5.23M
est: -17.36M (+69.9%)
|
-14.64M
est: -4.71M (-210.9%)
|
-18.95M
est: -17.78M (-6.6%)
|
-21.29M
est: -30.65M (+30.5%)
|
-15.22M
est: -93.11M (+83.7%)
|
-10.29M
est: 3.25M (-416.0%)
|
-14.25M
est: -4.74M (-200.6%)
|
-14.68M
est: -27.37M (+46.4%)
|
-19.73M
est: -19.97M (+1.2%)
|
-16.15M
est: -43.78M (+63.1%)
|
-15.64M
est: -60.56M (+74.2%)
|
-8.17M
est: -98.98M (+91.8%)
|
-9.99M
est: -17.52M (+43.0%)
|
-3.34M
-3.34M – -3.34M
+81.0% YoY
|
-834.4K
-834.4K – -834.4K
+75.0% YoY
|
11.68M
11.68M – 11.68M
+1,500.0% YoY
|
20.44M
20.44M – 20.44M
+75.0% YoY
|
| SGA |
1.52M
est: 2.79M (-45.7%)
|
2.85M
est: 2.74M (+4.1%)
|
2.47M
est: 2.79M (-11.8%)
|
6.23M
est: 11.70M (-46.7%)
|
4.47M
est: 2.89M (+54.4%)
|
4.15M
est: 6.90M (-39.9%)
|
4.89M
est: 3.74M (+30.9%)
|
4.39M
est: 8.35M (-47.4%)
|
4.45M
est: 11.19M (-60.3%)
|
3.99M
est: 18.25M (-78.1%)
|
4.67M
est: 2.27M (+105.8%)
|
6.27M
est: 2.15M (+191.4%)
|
5.18M
est: 12.04M (-56.9%)
|
6.89M
est: 10.29M (-33.1%)
|
6.86M
est: 9.54M (-28.1%)
|
7.03M
est: 28.63M (-75.5%)
|
7.24M
est: 5.14M (+40.8%)
|
3.03M
est: 8.62M (-64.9%)
|
28.99M
28.99M – 28.99M
+236.2% YoY
|
44.04M
44.04M – 44.04M
+51.9% YoY
|
68.81M
68.81M – 68.81M
+56.2% YoY
|
100.93M
100.93M – 100.93M
+46.7% YoY
|
| EPS |
-0.05
est: -0.05 (+9.7%)
|
-0.09
est: -0.07 (-25.0%)
|
0.00
est: -0.08 (+97.6%)
|
-0.04
est: -0.04 (+2.8%)
|
-0.05
est: -0.04 (-22.4%)
|
-0.02
est: -0.04 (+55.5%)
|
-0.05
est: -0.04 (-26.4%)
|
-0.06
est: -0.05 (-17.5%)
|
-0.06
est: -0.07 (+8.1%)
|
-0.04
est: -0.04 (-2.0%)
|
-0.03
est: -0.02 (-63.5%)
|
-0.04
est: -0.04 (-13.5%)
|
-0.04
est: -0.03 (-42.9%)
|
-0.05
est: -0.04 (-32.7%)
|
-0.04
est: -0.04 (+2.4%)
|
-0.04
est: -0.04 (+2.4%)
|
-0.02
est: -0.02 (+0.0%)
|
-0.02
est: -0.04 (+43.1%)
|
-0.01
-0.01 – -0.01
+81.0% YoY
|
0.00
0.00 – 0.00
+75.0% YoY
|
0.03
0.03 – 0.03
+1,500.0% YoY
|
0.05
0.05 – 0.05
+75.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.22M
OE per share TTM
-0.02
Owner's Yield
-2.80%
Maintenance CapEx ratio
179.06%
Maint CapEx / Avg PPE
73.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 32.1K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 20.9K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.0K
Shares Outstanding
420.93M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheryl Maley | Chief Executive Officer, MD & Director | 639.8K | female |
| Justin Cahill | Chief Financial Officer & Company Secretary | 392.4K | male |
| Miranda Sowden | Director of People & Culture | — | female |
| Sindy Smith | Communications & Investor Relations Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
